Abstract: A method of manufacturing a non-aqueous secondary battery includes the steps of preparing a case main body, preparing a lid, applying a lubricant to a contact location, and assembling a lid to an open end of the case main body. In the step of preparing a lid, a lid to be fitted to the open end of the case main body is prepared. In the step of applying a lubricant, the lubricant is applied to at least a portion of the contact location at which the case main body and the lid are in contact with each other. In the step of assembling the lid to the open end, the lid is assembled to the open end with the lubricant having been applied to the contact location. The lubricant may be a solvent used in a non-aqueous electrolyte solution for non-aqueous secondary batteries.

Abstract: A method of manufacturing a non-aqueous secondary battery includes the steps of preparing a case main body, preparing a lid, applying a lubricant to a contact location, and assembling a lid to an open end of the case main body. In the step of preparing a lid, a lid to be fitted to the open end of the case main body is prepared. In the step of applying a lubricant, the lubricant is applied to at least a portion of the contact location at which the case main body and the lid are in contact with each other. In the step of assembling the lid to the open end, the lid is assembled to the open end with the lubricant having been applied to the contact location. The lubricant may be a solvent used in a non-aqueous electrolyte solution for non-aqueous secondary batteries.

Abstract: The object of the present invention is to potentiate the photodynamic effect in ALA-PDT and ALA-PDD. The present invention provides a pharmaceutical related to a combination of ALAs and a dynamin inhibitor.

Abstract: The object of the invention is to elevate the stability of an aqueous formulation comprising ALAs and an iron compound. The present invention provides an aqueous formulation comprising ALAs and an iron compound, characterized in that it further comprises 0.2-30% by weight of salts, said salts are sodium salts or potassium salts, and the pH of said aqueous formulation is 2-8.

Abstract: A method of manufacturing a non-aqueous secondary battery includes the steps of preparing a case main body, preparing a lid, applying a lubricant to a contact location, and assembling a lid to an open end of the case main body. In the step of preparing a lid, a lid to be fitted to the open end of the case main body is prepared. In the step of applying a lubricant, the lubricant is applied to at least a portion of the contact location at which the case main body and the lid are in contact with each other. In the step of assembling the lid to the open end, the lid is assembled to the open end with the lubricant having been applied to the contact location. The lubricant may be a solvent used in a non-aqueous electrolyte solution for non-aqueous secondary batteries.

Abstract: The object of the present invention is to potentiate the photodynamic effect in ALA-PDT and ALA-PDD. The present invention provides a pharmaceutical related to a combination of ALAs and a dynamin inhibitor.

Abstract: The object of the invention is to elevate the stability of an aqueous formulation comprising ALAs and an iron compound. The present invention provides an aqueous formulation comprising ALAs and an iron compound, characterized in that it further comprises 0.2-30% by weight of salts, said salts are sodium salts or potassium salts, and the pH of said aqueous formulation is 2-8.

Abstract: A method for treating side effects of anticancer agent includes administering to a subject in need thereof a prophylactic and/or therapeutic agent containing a therapeutically effective amount of a compound shown by the following Formula (I): R1—NHCH2COCH2CH2COOR2??(I) wherein R1 represents a hydrogen atom or an acyl group, and R2 represents a hydrogen atom, a linear or branched alkyl group, a cycloalkyl group, an aryl group, or an aralkyl group, or a salt thereof.

Abstract: The object of the present invention is to elucidate the resistance mechanism in infections that show resistance to ALA-PDT that uses a single ALA, and to provide a novel treatment method against these infections. The present invention provides a pharmaceutical composition for promoting protoporphyrin IX production in ALA-PDT for treating infection, characterized in that it comprises a substance that promotes the conversion from coproporphyrinogen III to protoporphyrin IX.

Abstract: The objects of the present invention are to inhibit photobleaching of porphyrins as well as to provide a superior photodynamic diagnostic agent and a photodynamic diagnostic method employing the photobleaching inhibitor for porphyrins. The present invention provides a photodynamic diagnostic agent containing a precursor of porphyrins and a gallic acid. The present invention also provides a photobleaching inhibitor for porphyrins containing a gallic acid.

Abstract: It is to provide a tumor diagnostic agent and a tumor determination method enabling not only determination of the presence or absence of a tumor in a subject, but also determination of whether the tumor is a malignant tumor or a benign tumor, which can be used simply at low cost with reduced side effects and burden. 5-aminolevulinic acid (ALA) or its derivative, or a salt thereof is orally administered at a dose of 5 to 7 mg in terms of ALA per kg of body weight, and a urine sample 4 to 12 hours after the administration is collected. Porphyrins and creatinine in the urine sample are quantitated, and based on the value (nmol/gCre) obtained by dividing the amount of porphyrins by the amount of creatinine, a distinction among an individual without a tumor, an individual with a benign tumor, and an individual with a malignant tumor is determined. The presence or absence of a malignant tumor in a subject can be clearly determined by administering 1 to 3 mg of ALAs in terms of ALA per kg of body weight.

Abstract: The object of the present invention is to elucidate the resistance mechanism in infections that show resistance to ALA-PDT that uses a single ALA, and to provide a novel treatment method against these infections. The present invention provides a pharmaceutical composition for promoting protoporphyrin IX production in ALA-PDT for treating infection, characterized in that it comprises a substance that promotes the conversion from coproporphyrinogen III to protoporphyrin IX.

Abstract: According to the present invention, a tumor diagnostic agent which carries out early stage detection, monitoring of therapeutic effect and prognostic diagnosis of all tumors The tumor diagnostic agent of the present invention is a tumor diagnostic agent comprising ?-aminolevulinic acid represented by formula (I), a derivative thereof and a salt thereof: R2R1NCH2COCH2CH2COR3??(I) wherein R1 and R2 each independently represents hydrogen, alkyl, acyl, alkoxycarbonyl, aryl or aralkyl; and R3 represents hydroxy, alkoxy, acyloxy, alkoxycarbonyloxy, aryloxy, aralkyloxy or amino, which is used for diagnoses by measuring porphyrins in a sample collected from the inside or outside of the body after its administration.

Abstract: The objects of the present invention are to inhibit photobleaching of porphyrins as well as to provide a superior photodynamic diagnostic agent and a photodynamic diagnostic method employing the photobleaching inhibitor for porphyrins. The present invention provides a photodynamic diagnostic agent containing a precursor of porphyrins and a gallic acid. The present invention also provides a photobleaching inhibitor for porphyrins containing a gallic acid.

Abstract: A metal component absorption enhancer which enhances the absorption of at least one metal component selected from the elements belonging to groups 2 to 12 in the third to fourth periods when a plant grows. The metal component absorption enhancer contains 5-aminolevulinic acid or a derivative thereof represented by the following general formula (1), or a salt thereof as an active ingredient: R2R1NCH2COCH2CH2COR3??(1) wherein R1 and R2 each independently represents a hydrogen atom, an alkyl group, an acyl group, an alkoxycarbonyl group, an aryl group, or an aralkyl group; R3 represents a hydroxyl group, an alkoxy group, an acyloxy group, an alkoxycarbonyloxy group, an aryloxy group, an aralkyloxy group, or an amino group, and is used for performing a treatment with 0.001 to 20 ppm of the 5-aminolevulinic acid, the derivative thereof, or the salt thereof per each time.

Abstract: Provided is a sensitizing detection agent of an oral or intravenous administration type which enables the detection of bladder cancer with a higher sensitivity without causing pain to the patient. A sensitizing detection agent for bladder cancer comprising 5-aminolevulinic acid (ALA), a derivative thereof, or a salt of these is orally or intravenously administered, and a video camera system is inserted via the urethra and a blue light at 380-440 nm is irradiated to observe the red fluorescent part. Further, VLD-M1 is inserted and a blue light at 405 nm is irradiated to observe fluorescence intensity (relative intensity) of the red light part. For oral administration, 20 mg/kg (maximum of 1 g) of ALA is dissolved in 50 mL of a 5% glucose solution prior to the administration.

Abstract: It is to provide a tumor diagnostic agent and a tumor determination method enabling not only determination of the presence or absence of a tumor in a subject, but also determination of whether the tumor is a malignant tumor or a benign tumor, which can be used simply at low cost with reduced side effects and burden. 5-aminolevulinic acid (ALA) or its derivative, or a salt thereof is orally administered at a dose of 5 to 7 mg in terms of ALA per kg of body weight, and a urine sample 4 to 12 hours after the administration is collected. Porphyrins and creatinine in the urine sample are quantitated, and based on the value (nmol/gCre) obtained by dividing the amount of porphyrins by the amount of creatinine, a distinction among an individual without a tumor, an individual with a benign tumor, and an individual with a malignant tumor is determined. The presence or absence of a malignant tumor in a subject can be clearly determined by administering 1 to 3 mg of ALAs in terms of ALA per kg of body weight.

Abstract: To provide a therapeutic agent and a diagnostic agent for mitochondrial dysfunction brain diseases including cerebral infarction as a representative. A therapeutic agent for a mitochondrial dysfunction brain disease, which comprises (A) ?-aminolevulinic acid represented by the formula (1), a derivative thereof, or a salt thereof and (B) an iron compound in combination. R2R1NCH2COCH2CH2COR3??(1) wherein R1 and R2 each independently represents a hydrogen atom, an alkyl group, an acyl group, an alkoxycarbonyl group, an aryl group, or an aralkyl group; and R3 represents a hydroxy group, an alkoxy group, an acyloxy group, an alkoxycarbonyloxy group, an aryloxy group, an aralkyloxy group, or an amino group.

Abstract: A method for treating side effects of anticancer agent includes administering to a subject in need thereof a prophylactic and/or therapeutic agent containing a therapeutically effective amount of a compound shown by the following Formula (1): R1—NHCH2COCH2CH2COOR2 ??(I) wherein R1 represents a hydrogen atom or an acyl group, and R2 represents a hydrogen atom, a linear or branched alkyl group, a cycloalkyl group, an aryl group, or an aralkyl group, or a salt thereof.

Abstract: The present invention is drawn to a method of inducing thymocyte proliferation in a vertebrate animal with an impaired immune system comprising administering ?-aminolevulinic acid or a salt thereof every day in succession. The method further comprises administering at least one mineral.